Latest News and Press Releases

TUSTIN, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...

TUSTIN, Calif., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...

AD/PD Laboratories Open Exactly Eight Months After Announced Plans to Build Viral Vector Facility Build-Out of Facility’s CGMP Manufacturing Suites Continues, Expected to Come Online in...

New Laboratories Have Potential to Support an Additional $20 Million in Annual Process Development Revenue, Doubling Current Mammalian Cell Process Development Capacity Expansion to Cost...

TUSTIN, Calif., March 16, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...

TUSTIN, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...

TUSTIN, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...

-- Recorded Second Quarter Revenue of $26.1 Million -- -- Initiated Strategic Expansion into Viral Vector Development and Manufacturing Services for Cell and Gene Therapy -- -- Signed $36 Million in...

TUSTIN, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...

-- Recorded First Quarter Revenue of $30.8 Million -- -- Achieved Fifth Consecutive Quarter of Operational Profitability -- --  Signed $23 Million in New Business Orders and Ended the Quarter...